Zobrazeno 1 - 10
of 107
pro vyhledávání: '"biliary tract cancer (BTC)"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/6f7da840cf9c4fa78c32ecaafa8571ca
Publikováno v:
Shanghai Jiaotong Daxue xuebao. Yixue ban, Vol 43, Iss 9, Pp 1175-1185 (2023)
Objective·To comprehensively evaluate the diagnostic accuracy of cell-free DNA (cfDNA) to biliary tract cancer (BTC), and provide a basis for better clinical application.Methods·Clinical studies on the diagnostic value of cfDNA to BTC were collecte
Externí odkaz:
https://doaj.org/article/0ca540d724c74aa79341df0d16856d14
Autor:
Chiao-Ping Chen, Chun-Nan Yeh, Yi-Ru Pan, Wen-Kuan Huang, Yu-Tien Hsiao, Chih-Hong Lo, Chiao-En Wu
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115389- (2023)
Patients with advanced biliary tract cancer (BTC) have a poor prognosis, and novel treatments are needed. Gemcitabine, the standard of care for BTC, induces DNA damage; however, the ability of cancer cells to repair DNA dampens its effects. To improv
Externí odkaz:
https://doaj.org/article/28151b94a1054d259facfdc9571eff83
Autor:
Frontiers Production Office
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/42fd150a15c74444803fc5d8c0a8779a
Autor:
Hossein Taghizadeh, Angela Djanani, Wolfgang Eisterer, Armin Gerger, Birgit Gruenberger, Thomas Gruenberger, Holger Rumpold, Lukas Weiss, Thomas Winder, Ewald Wöll, Gerald W. Prager
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Locally advanced or metastatic cholangiocarcinoma is an aggressive carcinoma with a dismal prognosis. For the first-line treatment of locally advanced or metastatic cholangiocarcinoma, cisplatin/gemcitabine has been the standard of care for more than
Externí odkaz:
https://doaj.org/article/ac2eb60400d44723bdbe5729355db3ab
Autor:
Hannes Jansson, Martin Cornillet, Dan Sun, Iva Filipovic, Christian Sturesson, Colm J. O’Rourke, Jesper B. Andersen, Niklas K. Björkström, Ernesto Sparrelid
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionSystemic inflammatory markers have been validated as prognostic factors for patients with biliary tract cancer (BTC). The aim of this study was to evaluate specific immunologic prognostic markers and immune responses by analyzing preopera
Externí odkaz:
https://doaj.org/article/c3e7658b689242a6818b06ca97885cc3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Qi Jiang, Jinsheng Huang, Bei Zhang, Xujia Li, Xiuxing Chen, Bokang Cui, Shengping Li, Guifang Guo
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundAnti-programmed cell death protein 1 and its ligand (anti-PD1/PDL1) have been proposed as a promising therapeutic option for advanced biliary tract cancer (aBTC). Given the scarce quantitative analyses of anti-PD1/PDL1 in aBTC, we thus did
Externí odkaz:
https://doaj.org/article/9b9d1e6935714a9eb6f3d23bae22f72c
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Background: Selecting proper postoperative adjuvant therapy is of great importance for prolonging overall survival (OS) of patients with biliary tract cancer (BTC). OS is commonly affected by high rate of postoperative recurrence and metastasis.Purpo
Externí odkaz:
https://doaj.org/article/4afac92d515045a08af330182f6a7911
Autor:
Mitsuru Sugimoto, Kazumichi Abe, Manabu Hayashi, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Yuki Sato, Hiroki Irie, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Yuichi Waragai, Mika Takasumi, Minami Hashimoto, Takuto Hikichi, Yoshihiro Nozawa, Hiromasa Ohira
Publikováno v:
Scientific Reports, Vol 8, Iss 1, Pp 1-7 (2018)
Abstract In this study, we determined the efficacy of the cell death biomarker cytokeratin 18 for diagnosing biliary tract cancer (BTC). We recruited 36 patients with BTC (Malignant group) and 45 patients with benign biliary tract disease (Benign gro
Externí odkaz:
https://doaj.org/article/3a2bfe63fe304f33a6de52b0dae27cfd